Carmustine

Generic Name
Carmustine
Brand Names
Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
Drug Type
Small Molecule
Chemical Formula
C5H9Cl2N3O2
CAS Number
154-93-8
Unique Ingredient Identifier
U68WG3173Y
Background

A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...

Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Associated Conditions
Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-
Clinical Trials
Related News

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

First Posted Date
2003-11-24
Last Posted Date
2018-11-06
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
184
Registration Number
NCT00002836
Locations
🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Phase 2
Withdrawn
Conditions
Lymphoma
First Posted Date
2003-10-08
Last Posted Date
2017-11-29
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Registration Number
NCT00005998

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

First Posted Date
2003-10-07
Last Posted Date
2013-10-17
Lead Sponsor
Children's Oncology Group
Target Recruit Count
24
Registration Number
NCT00070187
Locations
🇺🇸

University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

Children's Hospital of Minnesota - Minneapolis, Minneapolis, Minnesota, United States

and more 60 locations

Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas

Phase 1
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2003-09-25
Last Posted Date
2013-02-18
Lead Sponsor
Duke University
Registration Number
NCT00003463
Locations
🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2003-09-18
Last Posted Date
2013-07-10
Lead Sponsor
University of Nebraska
Target Recruit Count
30
Registration Number
NCT00002638
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease

First Posted Date
2003-08-28
Last Posted Date
2013-01-24
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
11
Registration Number
NCT00005090
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

🇺🇸

University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States

and more 44 locations

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

First Posted Date
2003-08-11
Last Posted Date
2015-03-06
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
899
Registration Number
NCT00002548
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

🇺🇸

New England Medical Center Hospital, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 31 locations

Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Phase 2
Withdrawn
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2003-08-11
Last Posted Date
2013-03-28
Lead Sponsor
Duke University
Registration Number
NCT00046878

Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme

First Posted Date
2003-06-17
Last Posted Date
2016-12-07
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
58
Registration Number
NCT00027612

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

First Posted Date
2003-05-07
Last Posted Date
2013-05-09
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
451
Registration Number
NCT00060255
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy